Audited Standalone and Consolidated Financial Results along with Audit Report of the Company for the Quarter and Financial Year ended 31st March, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.6 pts less than Nifty Microcap 250 and 1.8 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Vivanza Biosciences reported a sharp deterioration in FY25 results. Standalone revenue from operations fell to Rs. 294.28 lakhs from Rs. 1,441.32 lakhs in FY24, an almost 80% year-on-year decline. The company swung from a standalone profit after tax of Rs. 31.74 lakhs in FY24 to a loss of Rs. 69.51 lakhs in FY25. On a consolidated basis (including Vivanza Lifesciences Pvt Ltd), revenue dropped to Rs. 742.33 lakhs from Rs. 2,783.5 lakhs, with a consolidated loss after tax of Rs. 67.41 lakhs against a profit of Rs. 54.73 lakhs last year. Operating cash flow turned sharply negative at around negative Rs. 247 lakhs on a standalone basis. Other equity eroded to just Rs. 2.04 lakhs from Rs. 71.53 lakhs. The auditor (Shivam Soni & Co.) issued a clean, unqualified opinion with no qualifications or going concern flag. The board also approved new appointments for Internal Auditor, Secretarial Auditor, and a new Independent Director.
Shareholders should view this as a negative quarter — revenues have collapsed, the company has slipped back into losses, and operating cash burn has worsened materially. The clean audit opinion provides some comfort, but the weak fundamentals could weigh on the stock and signal business stress worth monitoring.